Recital 161, Commission Decision of 12/12/2023 declaring a concentration to be compatible with the co…

In forcesince 12 Dec 2023

The Parties submit that, even if the merged entity decided to engage in an input

foreclosure strategy, this would not have a detrimental effect on the market.

Dairy customers may even be able to obtain better prices for the products when non-GM produced lactase in Denmark (combined [30-40]%, Chr. Hansen [10-20]% and Novozymes [20-30]%). 230 In Denmark, there is a hypothetically vertically affected market as a result of the Parties’ combined activity in the distribution of dairy enzymes. However, in Denmark, Chr. Hansen distributes coagulants and lactase and Novozymes distributes lactase. Since Novozymes is not active in the coagulant segment (neither at manufacturing nor distribution level), the vertical on the hypothetical dairy enzymes segment does not extend beyond the manufacture and distribution of lactase which is examined below. (Response to RFI 4). 231 The analysis is also applicable to other potential vertical links between the (i) upstream manufacturing of GM produced lactase and (ii) GM and non-GM produced lactase distribution segments and wider downstream enzymes distribution segments (F&B enzymes and dairy enzymes) at national, EEA and global level. 232 Novozymes’ market share does not exceed 30% on any plausible basis. At most, it is of [20-30]% in fact, in the market for the manufacture of lactase for the food & beverage industry in the EEA (excluding direct sales) (Form CO. para.1494). 233 Form CO. para. 1494. 234 Form CO. para. 1495. 235 Form CO. para. 1495. 236 Form CO. para. 1496. purchasing directly from the merged entity, as the final price would not include distributors’ own margins.

5.3.3.2. The Commission’s assessment